109 related articles for article (PubMed ID: 38777539)
21. Inherited mutations in breast cancer genes--risk and response.
Shuen AY; Foulkes WD
J Mammary Gland Biol Neoplasia; 2011 Apr; 16(1):3-15. PubMed ID: 21461995
[TBL] [Abstract][Full Text] [Related]
22. Pathology of hereditary breast cancer.
van der Groep P; van der Wall E; van Diest PJ
Cell Oncol (Dordr); 2011 Apr; 34(2):71-88. PubMed ID: 21336636
[TBL] [Abstract][Full Text] [Related]
23. Analysis of BRCA1/2 mutation spectrum and prevalence in unselected Chinese breast cancer patients by next-generation sequencing.
Li G; Guo X; Tang L; Chen M; Luo X; Peng L; Xu X; Wang S; Xiao Z; Yi W; Dai L; Wang J
J Cancer Res Clin Oncol; 2017 Oct; 143(10):2011-2024. PubMed ID: 28664449
[TBL] [Abstract][Full Text] [Related]
24. Penetrance estimates for
Evans DG; Woodward E; Harkness EF; Howell A; Plaskocinska I; Maher ER; Tischkowitz MD; Lalloo F
J Med Genet; 2018 Jul; 55(7):442-448. PubMed ID: 29483236
[TBL] [Abstract][Full Text] [Related]
25. Next-Generation Sequencing Identifies
Peker Eyüboğlu İ; Yenmiş G; Bingöl EN; Yüksel Ş; Tokat F; Özbek P; Güllü Amuran G; Yakıcıer C; Akkiprik M
OMICS; 2020 Jan; 24(1):5-15. PubMed ID: 31851867
[TBL] [Abstract][Full Text] [Related]
26. Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes from a dataset of 3,552 Japanese whole genomes (3.5KJPNv2).
Tokunaga H; Iida K; Hozawa A; Ogishima S; Watanabe Y; Shigeta S; Shimada M; Yamaguchi-Kabata Y; Tadaka S; Katsuoka F; Ito S; Kumada K; Hamanaka Y; Fuse N; Kinoshita K; Yamamoto M; Yaegashi N; Yasuda J
PLoS One; 2021; 16(1):e0236907. PubMed ID: 33428613
[TBL] [Abstract][Full Text] [Related]
27. Germline variants in hereditary breast cancer genes are associated with early age at diagnosis and family history in Guatemalan breast cancer.
Ren M; Orozco A; Shao K; Albanez A; Ortiz J; Cao B; Wang L; Barreda L; Alvarez CS; Garland L; Wu D; Chung CC; Wang J; Frone M; Ralon S; Argueta V; Orozco R; Gharzouzi E; Dean M
Breast Cancer Res Treat; 2021 Sep; 189(2):533-539. PubMed ID: 34196900
[TBL] [Abstract][Full Text] [Related]
28. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
[TBL] [Abstract][Full Text] [Related]
29. Four novel BRCA variants found in Chinese hereditary breast cancer patients by next-generation sequencing.
Liu PF; Zhuo ZL; Xie F; Wang S; Zhao XT
Clin Chim Acta; 2021 May; 516():55-63. PubMed ID: 33476590
[TBL] [Abstract][Full Text] [Related]
30. BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls.
Li A; Xie R; Zhi Q; Deng Y; Wu Y; Li W; Yang L; Jiao Z; Luo J; Zi Y; Sun G; Zhang J; Shi Y; Liu J
Gynecol Oncol; 2018 Oct; 151(1):145-152. PubMed ID: 30078507
[TBL] [Abstract][Full Text] [Related]
31. A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer.
Karami F; Mehdipour P
Biomed Res Int; 2013; 2013():928562. PubMed ID: 24312913
[TBL] [Abstract][Full Text] [Related]
32. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
[TBL] [Abstract][Full Text] [Related]
33. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
34. BRCA1 and BRCA2 mutations in ethnic Lebanese Arab women with high hereditary risk breast cancer.
El Saghir NS; Zgheib NK; Assi HA; Khoury KE; Bidet Y; Jaber SM; Charara RN; Farhat RA; Kreidieh FY; Decousus S; Romero P; Nemer GM; Salem Z; Shamseddine A; Tfayli A; Abbas J; Jamali F; Seoud M; Armstrong DK; Bignon YJ; Uhrhammer N
Oncologist; 2015 Apr; 20(4):357-64. PubMed ID: 25777348
[TBL] [Abstract][Full Text] [Related]
35. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
[TBL] [Abstract][Full Text] [Related]
36. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
[TBL] [Abstract][Full Text] [Related]
37. Breast cancer susceptibility testing: past, present and future.
Goldberg JI; Borgen PI
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1205-14. PubMed ID: 16925486
[TBL] [Abstract][Full Text] [Related]
38. Breast cancer risk for Korean women with germline mutations in BRCA1 and BRCA2.
Park B; Dowty JG; Ahn C; Win AK; Kim SW; Lee MH; Lee JW; Kang E; Hopper JL; Park SK
Breast Cancer Res Treat; 2015 Aug; 152(3):659-65. PubMed ID: 26195121
[TBL] [Abstract][Full Text] [Related]
39. Identification of BRCA1/2 founder mutations in Southern Chinese breast cancer patients using gene sequencing and high resolution DNA melting analysis.
Kwong A; Ng EK; Wong CL; Law FB; Au T; Wong HN; Kurian AW; West DW; Ford JM; Ma ES
PLoS One; 2012; 7(9):e43994. PubMed ID: 22970155
[TBL] [Abstract][Full Text] [Related]
40. Genetic testing in women with breast cancer: implications for treatment.
Paterson R; Phillips KA
Expert Rev Anticancer Ther; 2017 Nov; 17(11):991-1002. PubMed ID: 28853307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
